Advancing novel treatments for dry eye and ocular surgery


Kala Pharmaceuticals (NASDAQ: KALA) is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYSTM (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which we have submitted a NDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease, which is currently in Phase 3 clinical development.


Year Invested: 2009
Location: Waltham, Mass.
Visit: www.kalarx.com

Recent News

August 9, 2018
Kala Pharmaceuticals Reports Second Quarter 2018 Financial Results

August 8, 2018
Kala Pharmaceuticals to Present at the Wedbush PacGrow Healthcare Conference

July 31, 2018
Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye Disease

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner